Intra Cellular Therapies reported $77.41M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 116.57M 1.11M
Aptinyx Inc APTX:US USD 2.69M 2.99M
Biogen BIIB:US USD 3.93B 1.09B
Bristol Myers Squibb BMY:US USD 18.93B 1.98B
Cytokinetics CYTK:US USD 76.5M 9.65M
Esperion Therapeutics ESPR:US USD 82.34M 70K
Gilead Sciences GILD:US USD 10.42B 1.2B
Halozyme Therapeutics HALO:US USD 109.38M 90.13M
Intra Cellular Therapies ITCI:US USD 77.41M 6.78M
JAZZ PHA JAZZ:US USD 812.95M 107.51M
Marinus Pharmaceuticals MRNS:US USD 21.05M 2.06M
Minerva Neurosciences NERV:US USD 2.2M 1.21M
Nektar Therapeutics NKTR:US USD 83.99M 21M
Neurocrine Biosciences NBIX:US USD 485.1M 199.4M
Novartis NVS:US USD 28.16B 514M
Prothena PRTA:US USD 50.6M 10.49M
Supernus Pharmaceuticals SUPN:US USD 725.99M 9.55M
United Therapeutics UTHR:US USD 315.9M 15.6M
Vanda Pharmaceuticals VNDA:US USD 92.62M 4.22M